V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Agios Pharmaceuticals Executive Compensation (FY25)

AGIO · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Brian Goff
Latest say-on-pay support
=
June 18, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.

The Agios Pharmaceuticals brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
Data as of October 22, 2026Latest filing (8-K): June 18, 2026
14 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Agios Pharmaceuticals brief$1,500Get the executive brief
Velarion Member, one year
346 figures on this page: 335 cited to the filing that reported them, 11 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Brian Goff: $6,776,359 → $5,370,389 (20.7% lower)
CEO pay ratio: 20:1 → 18:1 (10.0% lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is Agios Pharmaceuticals' chief executive and what were they paid?
Brian Goff was paid $5,370,389 in total compensation as Chief Executive Officer for fiscal 2025. Goff's total was 20.7% lower than the $6,776,359 reported for fiscal 2024.
What was Agios Pharmaceuticals' say-on-pay result?
Shareholders supported the say-on-pay proposal with 97.6% of votes cast for or against in favor at the meeting held June 18, 2026 for fiscal 2025.
Which companies are in Agios Pharmaceuticals' peer group?
The disclosed peer group includes ACADIA Pharmaceuticals Inc., Amicus Therapeutics, Inc., Apellis Pharmaceuticals, Inc., Arcus Biosciences, Inc. and Axome Therapeutics, Inc., among others.
What is Agios Pharmaceuticals' chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2025 is 18:1, against median employee compensation of $303,140.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Brian Goff
Chief Executive Officer
◇◇◇◇◇—◇◇
Jacqualyn Fouse
Former Chief Executive Officer
Departed during or after this year
◇—◇◇◇—◇◇
Cecilia Jones
Chief Financial Officer
◇◇◇◇◇—◇◇
Richa Poddar
Former Chief Commercial Officer
Departed during or after this year
◇—◇◇——◇◇
Bruce Car
Former Chief Scientific Officer
Departed during or after this year
◇—◇◇——◇◇
Sarah Gheuens
Chief Medical Officer, Head of Research & Development
◇—◇◇◇—◇◇
James Burns
Chief Legal Officer
◇—◇◇◇—◇◇
Jonathan Biller
Former Chief Financial Officer, Head of Corporate Affairs
Departed during or after this year
◇—◇◇——◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Tsveta Milanova
Chief Commercial Officer
◇◇◇◇◇—◇◇
Brian Goff
Chief Executive Officer
◇—◇◇◇—◇◇
Sarah Gheuens
Chief Medical Officer, Head of Research & Development
◇—◇◇◇—◇◇
James Burns
Chief Legal Officer
◇—◇◇◇—◇◇
Cecilia Jones
Chief Financial Officer
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Brian Goff
Chief Executive Officer
◇—◇◇◇—◇◇
Sarah Gheuens
Chief Medical Officer, Head of Research & Development
◇—◇◇◇—◇◇
James Burns
Chief Legal Officer
◇—◇◇◇—◇◇
Cecilia Jones
Chief Financial Officer
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Brian Goff
Chief Executive Officer
◇—◇◇◇—◇◇
Krishnan Viswanadhan
Chief Corporate Development & Strategy Officer
◇◇◇◇◇—◇◇
Cecilia Jones
Chief Financial Officer
◇—◇◇◇—◇◇
James Burns
Chief Legal Officer
◇—◇◇◇—◇◇
Sarah Gheuens
Chief Medical Officer, Head of Research & Development
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Brian GoffRSU◇——◇——◇
Brian GoffPSU◇—◇—◇——
Brian GoffOPTION◇——◇—◇◇
Cecilia JonesRSU◇——◇——◇
Cecilia JonesOPTION◇——◇—◇◇
Cecilia JonesPSU◇—◇—◇——
Cecilia JonesRSU◇——◇——◇
James BurnsRSU◇——◇——◇
James BurnsPSU◇—◇—◇——
James BurnsOPTION◇——◇—◇◇
James BurnsRSU◇——◇——◇
Krishnan Viswanadhan Pharm.DPSU◇—◇—◇——
Krishnan Viswanadhan Pharm.DOPTION◇——◇—◇◇
Krishnan Viswanadhan Pharm.DRSU◇——◇——◇
Sarah GheuensPSU◇—◇—◇——
Sarah GheuensOPTION◇——◇—◇◇
Sarah GheuensRSU◇——◇——◇
Fiscal 2022, 2023 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
James BurnsOption◇—◇03/01/2034
Option◇—◇03/01/2033
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇03/01/2032
Option◇—◇03/01/2035
Sarah GheuensOption◇—◇03/01/2033
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇03/01/2034
Option◇—◇03/01/2032
Option◇—◇03/01/2035
Option◇—◇03/05/2035
Cecilia JonesOption◇—◇09/26/2032
RSU◇◇——
Option◇—◇03/01/2033
RSU◇◇——
Option◇—◇03/01/2035
RSU◇◇——
Option◇—◇03/01/2034
Brian GoffRSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇03/01/2033
Option◇—◇08/08/2032
Option◇—◇03/01/2034
Option◇—◇03/01/2035
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Jay Backstrom
◇◇◇———◇
Kaye Foster
Lead independent director
◇◇◇———◇
Jacqualyn A. Fouse
◇◇◇———◇
David Scadden
◇◇◇———◇
Jeffrey Capello
◇◇◇———◇
Cynthia Smith
◇◇◇———◇
Rahul Ballal
◇◇◇———◇
Maykin Ho
◇◇◇———◇
Catherine Owen Adams
◇◇◇———◇
David P. Schenkein
◇—————◇
Brian Goff served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Board chair premium◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Rsus/Options.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • ACADIA Pharmaceuticals Inc. ACAD
  • Amicus Therapeutics, Inc. FOLD
  • Apellis Pharmaceuticals, Inc. APLS
  • Arcus Biosciences, Inc. RCUS
  • Axome Therapeutics, Inc. AXSM
  • BioCryst Pharmaceuticals, Inc. BCRX
  • Blueprint Medicines Corporation BPMC
  • Crinetics Pharmaceuticals, Inc. CRNX
  • Intellia Therapeutics, Inc. NTLA
  • Mirum Pharmaceuticals, Inc. MIRM
  • Rhythm Pharmaceuticals, Inc. RYTM
  • Sage Therapeutics, Inc. SAGE
  • Soleno Therapeutics, Inc. SLNO
  • SpringWorks Therapeutics, Inc. SWTX
  • Syndax Pharmaceuticals, Inc. SNDX
  • TG Therapeutics, Inc. TGTX
  • Travere Therapeutics, Inc. TVTX
  • Ultragenyx Pharmaceutical Inc. RARE

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 18, 2026=◇◇◇
2024June 18, 2025=◇◇◇
2023June 20, 2024=◇◇◇
2022June 13, 2023=◇◇◇
2021June 21, 2022=◇◇◇
2020May 20, 2021=◇◇◇
2019May 28, 2020=◇◇◇
2018May 29, 2019=◇◇◇
2017May 31, 2018=◇◇◇
2016June 13, 2017=◇◇◇
2015June 21, 2016=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Brian Goff (Chief Executive Officer), FY2025 total compensation $5,370,389 (base salary $846,864) [exec_comp, SEC accession 0001193125-26-177086, filed 2026-04-24]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Agios Pharmaceuticals files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Agios Pharmaceuticals disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Agios Pharmaceuticals sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Agios Pharmaceuticals' disclosed peer group is defensible, who names Agios Pharmaceuticals back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
346 figures on this page: 335 cited to the filing that reported them, 11 calculated from figures it prints.
335 cited to the filing
11 calculated from the filing

Documents cited

  1. 0001193125-26-275879
  2. 0001193125-26-177086
  3. 0001193125-25-142745
  4. 0001193125-24-164555
  5. 0001193125-24-117951
  6. 0001193125-23-166855
  7. 0001193125-23-118490
  8. 0001193125-22-178757
    Item 5.07 Submission of Matters to a Vote of Security Holders
  9. 0001193125-21-169241
    Item 5.07 Submission of Matters to a Vote of Security Holders
  10. 0001193125-20-155665
    Item 5.07 Submission of Matters to a Vote of Security Holders
  11. 0001193125-19-162771
    Item 5.07 Submission of Matters to a Vote of Security Holders
  12. 0001193125-18-181717
    Item 5.07 Submission of Matters to a Vote of Security Holders
  13. 0001193125-17-203508
    Item 5.07 Submission of Matters to a Vote of Security Holders
  14. 0001193125-16-628914
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Agios Pharmaceuticals executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/AGIO (accessed 2026).
Short form: data: Velarion

The Agios Pharmaceuticals brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
14 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Agios Pharmaceuticals and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Agios Pharmaceuticals discloses

The companies named in AGIO's own disclosed peer group.

ACADIA Pharmaceuticals Inc.Amicus Therapeutics, Inc.Apellis Pharmaceuticals, Inc.Arcus Biosciences, Inc.Axome Therapeutics, Inc.BioCryst Pharmaceuticals, Inc.Blueprint Medicines CorporationCrinetics Pharmaceuticals, Inc.Intellia Therapeutics, Inc.Mirum Pharmaceuticals, Inc.Rhythm Pharmaceuticals, Inc.Sage Therapeutics, Inc.Soleno Therapeutics, Inc.SpringWorks Therapeutics, Inc.Syndax Pharmaceuticals, Inc.TG Therapeutics, Inc.Travere Therapeutics, Inc.Ultragenyx Pharmaceutical Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy